References
- Mayer RJ, Davis RB, Schiffer CA, et al: Comparative evaluation of intensive post-remission therapy with different dose schedules of ARA-C in adults with acute myeloid leukemia (AML): preliminaryresults of CALGB phase III study. Haemotologica 76(Suppl 4):97, 1991.
- Adriaansen HJ, Hooijkaas H, Kappers-Klunne MC, et al: Detection of minimal residual disease in ANLL patients by use of double immunologic analysis for TdT and a myeloid marker. J Cell Biochem (Suppl 15G):14, 1991.
- Meloni G, Tosti S, Vignetti M, et al: IL2 treatment for limited resistant disease in relapsed AML patients. Exp Hematol 19:19, 1991.
- Faber LM, Willemze R, Falkenburg, JHF: Leu-kemia-specific cytotoxic T lymphocyte (CTL) Conclones can be generated in vitro by stimulation of HLA-genotypically identical donor cells with recipient leukemic cells. Exp Hematol 19:19,1991.
- Wiemik PH, Dutcher JP, Todd M, et al: Polyethylene glycolated (PEG) interleukin-2 (IL-2)as maintenance therapy for acute myelogenous leukemia (AML) in second remission (CR). Blood 78(Suppl 1):42a, 1991.
- Santini V, van Putten W, Delwei, R, et al: Spontaneous in vitro proliferation of primary acute myeloid leukemia: clinical relevance. Blood 78(Suppl 1):45a, 1991.
- Siapak CA, Desforges JR, Fogaren T, et al: The treatment of acute myeloid leukemia (AML) in the elderly with low-dose cytarabine hydroxyurea and calcitriol. Blood 78(Suppl 1):50a, 1991.
- Caron PC, Co MS, Bull MK, et al: Humanized M195 (anti-CD33) monoclonal antibodies: potential for therapy of myelogenous leukemia. Blood 78(Suppl 1):268a, 1991.
- Warrell RP, Muindi J, Frankel SR, et al: Continuous treatment with all trans-retinoic acid progressively decreases plasma drug concentrations: implications for relapse and resistance in acute promyelocytic leukemia. Blood 78(Suppl 1):268a, 1991.
- Raza A, Yousuf N, Abbas A, et al: Cell cycle characteristics predict for remission duration (rem dur) in 122 standard risk newly diagnosed patients with acute myeloid leukemia (AML). Blood 78(Suppl 1):380a, 1991.
- Van Etten RA: Distinct effect of expression of the all-specific form of BCR/ ABL P190 bcr/ abl in murine bone marrow. Blood 78(Suppl 1):28a, 1991.
- Uckun FM, Manivel JC, Gunther R, et al: Human B-lineage acute lymphoblastic leukemia (ALL) in severe combined immunodeficiency (SCID) mice: ability of primary leukemic B-cell precursors (BCP) from newly diagnosed B-lineage ALL patients to cause leukemia in immunodeficient CB.17 SCID mice may be associated with poor clinical outcome. Blood 78(Suppl 1):382a, 1991.
- Higano CS, Raskind W, Singer JW: Alpha interferon (ifn) treatment of chronic myelogenous leukemia (CML) in relapse after allogeneic marrow transplantation (BMT): a prospective trial. Blood 78(Suppl 1):290a, 1991.
- Yuan TY, Chen HC, Herst CV, et al: Antisense oligonucleotides to BRC-ABL mRNA inhibit synthesis of p <super-script>210</super-script> BCR ABL protein and reduce viability in cultures of Philadelphia chromosome positive cells. Blood 78(Suppl 1):329a, 1991.
- Burke PJ: Remission of aggressive phase chronic myelocytic leukemia (CML) with timed sequential therapy (TST) and interferon (I) given in aplasia. Haematologica 76(Suppl 4):38, 1991.
- Escudier SM, Pereira-Leahy JM, Goodacre AM, et al: Fluorescence in situ hybridization (FISH) and cytogenetic studies of trisomy 12 in chronic lymphocytic leukemia (CLL). Blood 78(Suppl 1):3291, 1991.
- del Giglio A, Khetan R, O'Brien S, et al: Proliferating cell nuclear antigen levels are high in advanced stage chronic lymphocytic leukemia and correlate with clinical doubling time of this disease. Blood 78(Suppl 1):311a, 1991.
- Juliusson G, Liliemark J: 2-Chloro-2'-deoxyadenosine (CdA) induces complete remission in B-cell chronic lymphocytic leukemia cells resistant to fludarabine (FAMP). Blood 78(Suppl 1):269a, 1991.
- Robertson L, Chubb S, Hittelman WN, et al: Programmed death (apoptosis) in chronic lymphocytic leukemia cells after fludarabine and chlorodeoxyadenosine. Blood 78(Suppl 1): 123a, 1991.
- van Kooten C, Rensink HJAM, Aarden LA, et al: TNFa-induced proliferation of B-chronic lymphocytic leukemia cells is inhibited by IL4. Blood 78(Suppl 1):112a, 1991.
- Kemena A, Keating JMJ, Plunkett W: Plasma and cellular bioavailability of oral fludarabine. Blood 78(Suppl 1):52a, 1991.
- Villalona-Calero M, Stewart C, Barcos M, et al: Phenotypic characteristics of “prolymphocytoid” transformed (CLL/PLL) chronic lymphocytic leukemia (CLL) cells. Proc ASCO 1OL:230, 1991.